表观遗传学
表型
机制(生物学)
人口
计算生物学
生物
功能(生物学)
突变
癌细胞
表型可塑性
药品
癌症
后生
适应性进化
适应性反应
可塑性
抗药性
遗传学
抗癌药
表型转换
细胞
细胞生物学
过程(计算)
损失函数
神经科学
药物开发
化学
癌变
非正面反馈
系统生物学
癌细胞系
蛋白质-蛋白质相互作用
过渡(遗传学)
细胞存活
作者
Ruth Nussinov,Hyunbum Jang
标识
DOI:10.1038/s41416-026-03649-x
摘要
Specific genetic mutations serve as clues to cancer emergence. However, non-genetic cell state shift mechanisms-such as the epithelial-to-mesenchymal transition (EMT)-drive swift, reversible drug tolerance and metastasis. Unlike the slow process of acquiring mutations, this plasticity allows rapid, drug-tolerant cells to revert to previous states upon withdrawal of the drug, thereby driving pharmacological resistance. Insight into the evolution of cell states in cancer is critical for optimizing drug regimens. Here we propose dynamic conformational heterogeneity as an untapped fundamental driver of adaptive resistance. Proteins do not function as simple binary switches; rather, they exist as dynamic ensembles. Cancer arises when their conformational distribution shifts permanently towards an active state. Drugs operate by selecting specific (oncogenic) 3D conformer shapes and reverse-shifting the population back to a stabilized inactive state. Epigenetic dysregulation in cancer cells amplifies expression levels of these proteins, shifting the ensemble toward the oncogenic state. The increased abundance of the active state saturates the networks, overcoming feedback controls. We propose that effectively countering cancer evolution requires drug combinations that target oncogenic conformations at both molecular and systems levels, including adaptive phenotypic plasticity factors, shifting focus from individual static targets to dynamic population states.
科研通智能强力驱动
Strongly Powered by AbleSci AI